Table 2.
Treatment related toxicity
| Cohort 1 MPA monotherapy |
Cohort 2 MPA + ldCM |
Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| Grade |
Grade |
Grade |
|||||||
| 2 | 3 | 4 | 2 | 3 | 4 | 2 | 3 | 4 | |
| Nausea | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Dysgeusia | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Mucositis | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Dysphagia | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Fatigue | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 1 | 0 |
| Pain | 3 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 |
| Dyspnea | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 |
| Hot flashes | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Irregular menses | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Insomnia | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Diaphoresis | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Rash | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
| Hypokalemia | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Transaminase elevated | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Alkaline phosphatase elevated | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Renal failure | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Dehydration | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
Worst toxicity reported per patient based on NCI-CTC v3.0